DLL3 Targeted Therapies
1 drugsAbout DLL3
Delta-like protein 3 (DLL3) is a transmembrane protein involved in the Notch signaling pathway, a regulator of cell fate decisions. Aberrant Notch signaling is implicated in cancer development, making DLL3 a potential target for cancer therapies.
DLL3 is a protein target of interest in oncology, though no genetic evidence directly links DLL3 to specific diseases. Its role in cellular signaling pathways makes it a compelling target for therapeutic intervention in certain cancers.
DLL3 is targeted by one FDA-approved drug, IMDELLTRA, a biologic. Amgen is the sole company with an approved DLL3-targeting therapy in oncology.
Top DLL3 Drugs
Amgen is currently the only company with an approved DLL3-targeting drug.
The market is highly concentrated, suggesting high barriers to entry for new competitors.
DLL3 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets DLL3, using biologic (other) modality.
The absence of small molecule DLL3 inhibitors represents a potential whitespace opportunity.
DLL3 Clinical Trials 35 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on DLL3. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 13 | 2 | 1 | 10 | 67% |
| Phase 2 | 15 | 0 | 1 | 14 | 0% |
| Phase 3 | 7 | 0 | 0 | 7 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
DLL3 Drug Approval Timeline (2024 - 2024)
The first and most recent DLL3-targeting drug, IMDELLTRA, was approved in 2024.
The recent approval suggests a growing interest in DLL3 as a therapeutic target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 20 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on DLL3. A trial counts if an approved drug acting on DLL3 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.